Neuroprotectin D1 synthesis via lipoxygenase pathway (NPD1 synthesis (via LOX pathway))

Neuroprotectin D1 synthesis via the lipoxygenase pathway refers to the multi-step enzymatic conversion of docosahexaenoic acid (DHA), an omega‑3 polyunsaturated fatty acid abundant in neural tissues and retina, into neuroprotectin D1 (NPD1). This process is initiated by phospholipase A₂–mediated release of free DHA from membrane phospholipids. Subsequently, 15‑lipoxygenase‑type I acts on DHA to generate a hydroperoxy intermediate [17S-H(p)DHA], which is further converted through epoxide intermediates into NPD1—a bioactive lipid mediator with potent anti-inflammatory and anti-apoptotic properties. Alternative stereoselective syntheses have been described for laboratory production. The biological significance of this synthetic route lies in its role during cellular stress responses such as oxidative injury or inflammation in brain and retinal cells; upregulation leads to increased local concentrations of NPD1 that promote cell survival by modulating gene expression programs favoring anti-inflammation and cell protection over apoptosis. In summary: “Neuroprotectin D1 synthesis via lipoxygenase pathway” does not refer to a single canonical drug target but rather describes an important biochemical route involving specific enzymes—most notably arachidonate 15‑lipoxygenase type I—that produce neuroprotective lipid mediators from dietary omega‑3 fatty acids.

Other names

NPD1 biosynthesisProtectin D1 synthesisDHA-derived docosatriene biosynthesisLipoxygenase-mediated NPD1 formation